2017
Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival
Yang JC, Risch E, Zhang M, Huang C, Huang H, Lu L. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival. Future Oncology 2017, 13: 1981-1990. PMID: 28829218, DOI: 10.2217/fon-2017-0084.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedAged, 80 and overBiomarkers, TumorCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor IIMethyltransferasesMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPrognosisSurvival RateConceptsOvarian cancer survivalIGF-IICancer survivalOvarian cancerDisease progression-free survivalMultivariate Cox regression modelProgression-free survivalRisk of deathCox regression modelIGF-II expressionClinical followSurvival analysisClinical implicationsIGFNormal tissuesHeterogeneous outcomesSurvivalCancerMolecular signaturesAssociationRegression modelsRNA sequencingSupNSUN2Relapse
2016
LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis
Lu L, Katsaros D, Canuto EM, Biglia N, Risch HA, Yu H. LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis. Gynecologic Oncology 2016, 141: 121-127. PMID: 26751131, DOI: 10.1016/j.ygyno.2015.12.035.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancer prognosisOvarian cancer prognosisMolecular subtypesCancer prognosisSurvival analysisMultivariate Cox regression modelKaplan-Meier survival curvesEpithelial ovarian cancer tissuesCox regression modelEpithelial ovarian cancerReduced relapse riskOvarian cancer tissuesIGF-II mRNAQuantitative reverse transcription PCRRelapse riskReverse transcription-PCROvarian cancerBetter survivalCancer tissuesLin-28BSurvival curvesClinical implicationsIGFPrognosisSubtypes
2015
Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis
Wang Z, Katsaros D, Shen Y, Fu Y, Canuto EM, Benedetto C, Lu L, Chu WM, Risch HA, Yu H. Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis. PLOS ONE 2015, 10: e0136246. PMID: 26287798, PMCID: PMC4546117, DOI: 10.1371/journal.pone.0136246.Peer-Reviewed Original ResearchConceptsBreast cancer prognosisCancer prognosisGene expression signaturesExpression signaturesPoor disease-free survivalDisease-free survivalBreast cancer patientsBreast cancer cell linesBreast cancer progressionMDA-MB-468Tumor cell growthMDA-MB-231Multiple gene expression signaturesCancer cell linesAggressive tumorsCancer patientsClinical significanceDisease outcomeTumor featuresClinical implicationsPrognosisCancer progressionBiologic relevanceHigh expressionCell proliferation
2010
IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.
Qian B, Katsaros D, Lu L, Canuto EM, Benedetto C, Beeghly-Fadiel A, Yu H. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncology Reports 2010, 25: 203-13. PMID: 21109978, PMCID: PMC3075064, DOI: 10.3892/or_00001062.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease-Free SurvivalDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionConceptsInsulin-like growth factor IIEpithelial ovarian cancerOvarian cancerDisease progressionResidual tumor sizeIGF-II peptideFresh tumor samplesIGF-II expressionPromoter-specific expressionIGF-II mRNAGrowth factor IIIGF-II promotersLower mRNA expressionOverall survivalAggressive diseasePoor prognosisTumor sizeDisease characteristicsMethylation-specific PCRTumor gradeTreatment responseIGF-II transcriptionPromoter-specific methylationClinical implicationsCancer